Molecules containing the pyrazole nucleus are widely reported as promising candidates to develop new antimicrobial compounds against multidrug‐resistant (MDR) bacteria, where available antibiotics may fail. Recently, aiming at improving the too‐high minimum inhibitory concentrations (MICs) of a pyrazole hydrochloride salt (CB1H), CB1H‐loaded nanoparticles (CB1H‐ P7 NPs) were developed using a potent cationic bactericidal macromolecule (P7) as polymer matrix. Here, CB1H‐P7 NPs have been successfully tested on several clinical isolates of Gram‐positive and Gram‐negative species, including relevant MDR strains. CB1H‐P7 NPs displayed very low MICs (0.6–4.8 μM), often two‐fold lower than those of P7, on 34 out of 36 isolates tested. Upon complexation, the antibacterial effects of pristine CB1H were improved by 2–16.4‐fold, and, unexpectedly, also the already potent antibacterial effects of P7 were 2–8 times improved against most of bacteria tested when complexed with CB1H. Time‐killing experiments performed on selected species established that CB1H‐P7 NPs were bactericidal against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Selectivity indices values up to 2.4, determined by cytotoxicity experiments on human keratinocytes, suggested that CB1H‐P7 NPs could be promising for counteracting serious infections sustained by most of the isolates tested in this study

Enhanced Antibacterial Activity of a Cationic Macromolecule by Its Complexation with a Weakly Active Pyrazole Derivative

Schito, Anna Maria;Caviglia, Debora;Brullo, Chiara;Alfei, Silvana
2022-01-01

Abstract

Molecules containing the pyrazole nucleus are widely reported as promising candidates to develop new antimicrobial compounds against multidrug‐resistant (MDR) bacteria, where available antibiotics may fail. Recently, aiming at improving the too‐high minimum inhibitory concentrations (MICs) of a pyrazole hydrochloride salt (CB1H), CB1H‐loaded nanoparticles (CB1H‐ P7 NPs) were developed using a potent cationic bactericidal macromolecule (P7) as polymer matrix. Here, CB1H‐P7 NPs have been successfully tested on several clinical isolates of Gram‐positive and Gram‐negative species, including relevant MDR strains. CB1H‐P7 NPs displayed very low MICs (0.6–4.8 μM), often two‐fold lower than those of P7, on 34 out of 36 isolates tested. Upon complexation, the antibacterial effects of pristine CB1H were improved by 2–16.4‐fold, and, unexpectedly, also the already potent antibacterial effects of P7 were 2–8 times improved against most of bacteria tested when complexed with CB1H. Time‐killing experiments performed on selected species established that CB1H‐P7 NPs were bactericidal against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Selectivity indices values up to 2.4, determined by cytotoxicity experiments on human keratinocytes, suggested that CB1H‐P7 NPs could be promising for counteracting serious infections sustained by most of the isolates tested in this study
File in questo prodotto:
File Dimensione Formato  
biomedicines-10-01607.pdf

accesso aperto

Descrizione: articolo completo
Tipologia: Documento in versione editoriale
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/1092097
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact